HUTCHMED (China) Limited (AIM:HCM)
226.00
+1.00 (0.44%)
Jan 22, 2026, 4:35 PM GMT
HUTCHMED (China) Employees
HUTCHMED (China) had 1,811 employees as of December 31, 2024. The number of employees decreased by 177 or -8.90% compared to the previous year.
Employees
1,811
Change (1Y)
-177
Growth (1Y)
-8.90%
Revenue / Employee
246.93K GBP
Profits / Employee
191.45K GBP
Market Cap
1.93B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 1,811 | -177 | -8.90% |
| Dec 31, 2023 | 1,988 | -37 | -1.83% |
| Dec 31, 2022 | 2,025 | 265 | 15.06% |
| Dec 31, 2021 | 1,760 | 480 | 37.50% |
| Dec 31, 2020 | 1,280 | 427 | 50.06% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Haleon | 24,561 |
| Hikma Pharmaceuticals | 9,500 |
| Allergy Therapeutics | 584 |
| ECO Animal Health Group | 224 |
| Animalcare Group | 201 |
| Animalcare Group | 201 |
| Shield Therapeutics | 63 |
| Venture Life Group | 43 |
HUTCHMED (China) News
- 8 days ago - HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet - GlobeNewsWire
- 15 days ago - Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026 - Benzinga
- 15 days ago - Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026 - Benzinga
- 15 days ago - HUTCHMED's ESLIM-02 Trial Of Sovleplenib In Warm Autoimmune Hemolytic Anemia Meets Key Goal - Nasdaq
- 15 days ago - HUTCHMED's Sovleplenib Reaches Phase III Goal In Warm Autoimmune Hemolytic Anemia Trial In China - Nasdaq
- 15 days ago - HCM's Sovleplenib Trial Achieves Key Milestone in Treating Autoimmune Hemolytic Anemia - GuruFocus
- 15 days ago - HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China - GlobeNewsWire
- 17 days ago - HUTCHMED Begins Phase 3 Part Of Phase 2/3 Surufatinib-Camrelizumab Combo Study In Pancreatic Cancer - Nasdaq